PMID- 16625093
OWN - NLM
STAT- MEDLINE
DCOM- 20060518
LR  - 20211203
IS  - 0147-5185 (Print)
IS  - 0147-5185 (Linking)
VI  - 30
IP  - 4
DP  - 2006 Apr
TI  - Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) 
      simulates monomorphic B-cell PTLD both clinically and pathologically.
PG  - 470-6
AB  - Although Hodgkin lymphoma-like posttransplantation lymphoproliferative disorder 
      (HL-like PTLD) has been grouped with classic Hodgkin lymphoma type PTLD 
      (HL-PTLD), controversy remains as to whether it is truly a form of HL or whether 
      it should be more appropriately classified as a form of B-cell PTLD. Because only 
      few cases of HL-like PTLD have been reported, their pathologic nature and 
      clinical behavior have not been well defined. This report characterized 5 cases 
      of HL-like PTLD with respect to their immunophenotype, EBV status, clonality, and 
      clinical outcome. All of the patients were male, with ages ranging from 1.5 to 55 
      years at diagnosis. PTLD developed from 4 months to 6 years following solid organ 
      transplantation (3 hearts, 1 kidney, 1 liver), and involved both nodal and 
      extranodal sites. All were EBV-related (EBER+) with the large neoplastic cells 
      CD20/CD79a positive but CD15 negative. Immunoglobulin gene rearrangements were 
      detected in 3 of 5 tested. All patients were managed by initial 
      reduction/withdrawal of immunosuppression, with 2 also receiving chemotherapy for 
      non-HL. Three patients died of progressive disease within 2 to 3 months after 
      diagnosis, 1 is alive and well 2 years later, and the fifth was disease free but 
      died of unrelated causes (graft coronary disease) 2 years later. We conclude 
      that, although HL-like PTLD morphologically simulates classic HL PTLD, there are 
      important immunophenotypic, molecular genetic, and clinical differences, 
      suggesting it is in fact most often a B-cell PTLD. Distinction between HL and 
      HL-like PTLD may be important for clinical management and prognosis.
FAU - Pitman, Sean D
AU  - Pitman SD
AD  - Department of Pathology and Laboratory Medicine, Loma Linda University Medical 
      Center, Loma Linda, CA 92354, USA.
FAU - Huang, Qin
AU  - Huang Q
FAU - Zuppan, Craig W
AU  - Zuppan CW
FAU - Rowsell, Edward H
AU  - Rowsell EH
FAU - Cao, Jeffrey D
AU  - Cao JD
FAU - Berdeja, Jesus G
AU  - Berdeja JG
FAU - Weiss, Lawrence M
AU  - Weiss LM
FAU - Wang, Jun
AU  - Wang J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Epstein-Barr virus encoded RNA 1)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - B-Lymphocytes/*pathology
MH  - Child
MH  - Clone Cells
MH  - DNA, Neoplasm/analysis
MH  - Diagnosis, Differential
MH  - Epstein-Barr Virus Infections/complications/pathology
MH  - Gene Rearrangement, B-Lymphocyte, Heavy Chain/genetics
MH  - Hodgkin Disease/*etiology/*pathology/therapy
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunosuppression Therapy
MH  - Infant
MH  - Lymphoproliferative Disorders/*etiology/*pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Organ Transplantation/*adverse effects
MH  - Postoperative Complications
MH  - RNA, Viral/analysis
EDAT- 2006/04/21 09:00
MHDA- 2006/05/19 09:00
CRDT- 2006/04/21 09:00
PHST- 2006/04/21 09:00 [pubmed]
PHST- 2006/05/19 09:00 [medline]
PHST- 2006/04/21 09:00 [entrez]
AID - 00000478-200604000-00007 [pii]
AID - 10.1097/00000478-200604000-00007 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2006 Apr;30(4):470-6. doi: 10.1097/00000478-200604000-00007.